All articles tagged with #p tau217
A recent study reveals that both newborns and Alzheimer's patients have elevated levels of the brain protein p-tau217, which plays different roles in each group—supporting healthy brain development in infants and indicating neurodegeneration in Alzheimer's. The findings suggest that understanding how the healthy brain manages tau could lead to new treatments for Alzheimer's disease.
New research reveals high levels of the Alzheimer's-associated protein p-tau217 in healthy newborns, suggesting it plays a crucial role in brain development rather than solely causing neurodegeneration, challenging existing assumptions and opening new avenues for understanding and treating Alzheimer's disease.
A study found that healthy newborns have higher levels of the Alzheimer’s-linked protein p-tau217 than dementia patients, suggesting this protein plays a crucial role in early brain development rather than solely causing neurodegeneration. This discovery challenges existing beliefs about tau proteins and could lead to new approaches in treating or preventing Alzheimer’s disease by understanding how infant brains manage high tau levels safely.
A study found that newborns and Alzheimer's patients both have elevated levels of the biomarker p-tau217, but in newborns, this protein supports healthy brain development, whereas in Alzheimer's it is associated with disease progression. The findings suggest potential pathways for new treatments by understanding how the healthy brain regulates tau protein.
A new study suggests that a blood test screening for Alzheimer’s disease using a protein called p-tau217 could be highly accurate in identifying key biomarkers of the disease, even before symptoms appear. The test, which is commercially available for research use, showed up to 96% accuracy in identifying elevated levels of beta amyloid and up to 97% accuracy in identifying tau, making it comparable to advanced testing methods like brain scans and spinal taps. This development could lead to improved patient management, timely access to therapies, and more cost-effective and accessible diagnostic options for the growing number of people at risk for Alzheimer's disease.